In the last paragraph of Section 1, the sentence “VDZ is a monoclonal antibody blocking the α4β7 integrin which is selectively expressed by the vascular endothelium in the gastrointestinal tract [7]” should be replaced with: “VDZ is a monoclonal antibody blocking the α4β7 integrin which is selectively expressed by the activated GUT homing lymphocytes [7]”. Mariabeatrice Principi, Gastroenterology Section, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy, should have been listed in Appendix A (Members of the GIVI Study Group).

Erratum: Corrigendum to “Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease” (Dig. Liver Dis. (2016) 48(4) (360–370))

PRINCIPI, MARIABEATRICE;
2016-01-01

Abstract

In the last paragraph of Section 1, the sentence “VDZ is a monoclonal antibody blocking the α4β7 integrin which is selectively expressed by the vascular endothelium in the gastrointestinal tract [7]” should be replaced with: “VDZ is a monoclonal antibody blocking the α4β7 integrin which is selectively expressed by the activated GUT homing lymphocytes [7]”. Mariabeatrice Principi, Gastroenterology Section, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy, should have been listed in Appendix A (Members of the GIVI Study Group).
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11586/171741
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 2
social impact